Genetically engineered mouse models of pancreatic adenocarcinoma. Issue 2 (11th February 2013)

• Record Type: Journal Article
• Authors: Guerra, Carmen; Barbacid, Mariano
• Other Names: Barbacid Mariano specialEditor.; Berns Anton specialEditor.
• Is Part Of: Molecular oncology. Volume 7:Issue 2(2013)
• Page Start: 232
• Page End: 247
• Publication Date: 2013-02-11
• Subjects: Cancer models -- Pancreatic ductal adenocarcinoma -- Tumor microenvironment -- Inflammation -- Target validation -- Therapeutic strategies; Cancer -- Molecular aspects -- Periodicals; 616.994005
• DOI: 10.1016/j.molonc.2013.02.002
• Languages: English
• ISSNs: 1574-7891

Abstract

Abstract : Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of human cancer for which there are no effective therapies. Deep sequencing of PDAC tumors has revealed the presence of a high number of mutations (>50) that affect at least a dozen key signaling pathways. This scenario highlights the urgent need to develop experimental models that faithfully reproduce the natural history of these human tumors in order to understand their biology and to design therapeutic approaches that might effectively interfere with their multiple mutated pathways. Over the last decade, several models, primarily based on the genetic activation of resident KRas oncogenes knocked‐in within the endogenous KRas locus have been generated. These models faithfully reproduce the histological lesions that characterize human pancreatic tumors. Decoration of these models with additional mutations, primarily involving tumor suppressor loci known to be also mutated in human PDAC tumors, results in accelerated tumor progression and in the induction of invasive and metastatic malignancies. Mouse PDACs also display a desmoplastic stroma and inflammatory responses that closely resemble those observed in human patients. Interestingly, adult mice appear to be resistant to PDAC development unless the animals undergo pancreatic damage, mainly in the form of acute, chronic or even temporary pancreatitis. In this review, we describe the most representative models available to date and how their detailed characterization is allowing us to understand their cellular origin as well as the events involved in tumor progression. Moreover, their molecular dissection is starting to unveil novel therapeutic strategies that could be translated to the clinic in the very near future.